F A de Jong
Overview
Explore the profile of F A de Jong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirza M, Benigno B, Dorum A, Mahner S, Bessette P, Barcelo I, et al.
Gynecol Oncol
. 2020 Sep;
159(2):442-448.
PMID: 32981695
Objective: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response...
2.
Issa D, Gelderblom H, Lugtenburg P, van Herk-Sukel M, Houweling L, De La Orden M, et al.
Eur J Cancer Care (Engl)
. 2014 Feb;
24(2):232-41.
PMID: 24528512
Few data have been published on healthcare resource utilisation associated with chemotherapy-induced febrile neutropenia (FN) in Europe. Using the PHARMO record linkage system, we identified incident adult patients with a...
3.
Krens L, Baas J, de Jong F, Guchelaar H, Gelderblom H
Cancer Chemother Pharmacol
. 2013 Nov;
73(2):429-33.
PMID: 24258455
Purpose: Panitumumab is used for the treatment for metastatic RAS wild-type colorectal cancer (mCRC). It is likely that many of these patients will present with liver metastases and some with...
4.
van Hellemond I, Creemers G, van Warmerdam L, de Jong F, Koornstra R
Clin Oncol (R Coll Radiol)
. 2013 Nov;
26(3):135-41.
PMID: 24246276
Aims: To report our clinical experience of panitumumab monotherapy as a second-line treatment for patients with metastatic colorectal cancer (mCRC). Materials And Methods: This retrospective, descriptive study included a series...
5.
Baas J, Krens L, Guchelaar H, Ouwerkerk J, de Jong F, Lavrijsen A, et al.
Cancer Treat Rev
. 2011 Nov;
38(5):505-14.
PMID: 22100458
Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequently result in skin toxicity,...
6.
de Jong F, van der Bol J, Mathijssen R, van Gelder T, Wiemer E, Sparreboom A, et al.
Clin Pharmacol Ther
. 2008 Feb;
84(2):254-62.
PMID: 18288083
Although approximately half of the administered dose of irinotecan is recovered in urine, scarce data are available on the association of renal function with irinotecan pharmacokinetics and toxicity. Here, these...
7.
Perik P, Rikhof B, de Jong F, Verweij J, Gietema J, van der Graaf W
Ann Oncol
. 2007 Oct;
19(2):359-61.
PMID: 17962203
Background: Recently, case reports of patients treated with imatinib (imatinib mesylate; Gleevec; Glivec) indicated that this tyrosine kinase inhibitor may induce cardiomyopathy. Consequently, careful cardiac monitoring was advocated for clinical...
8.
de Jong F, Verweij J, Sparreboom A
Int J Gynecol Cancer
. 2007 Oct;
18(5):1152.
PMID: 17944911
No abstract available.
9.
de Jong F, Scott-Horton T, Kroetz D, McLeod H, Friberg L, Mathijssen R, et al.
Clin Pharmacol Ther
. 2006 Dec;
81(1):42-9.
PMID: 17185998
Interindividual pharmacokinetic variability of the anticancer agent irinotecan is high. Life-threatening diarrhea is observed in up to 25% of patients receiving irinotecan and has been related with irinotecan pharmacokinetics and...
10.
de Jong F, Mathijssen R, Verweij J
J Chemother
. 2005 Jan;
16 Suppl 5:48-50.
PMID: 15675478
Intravenously administered irinotecan has gained an important place in the struggle against metastatic and/or irresectable colorectal cancer. In patients with irresectable metastases confined to the liver, hepatic arterial infusion (HAI)...